Showing results (1911-1920 of 1,956) with videos related to
Sort By:
Pageof 196
Nature Communications|November 17, 2023
Multi-omics for studying and understanding polar lifeM S Clark, J I Hoffman, L S Peck, et al.Science (New York, N.Y.)|July 27, 2002
Whole-genome shotgun assembly and analysis of the genome of Fugu rubripesSamuel Aparicio, Jarrod Chapman, Elia Stupka, et al.Physical Review. E|November 18, 2025
Effect on compression of lowering the design adiabat in the SQ-n campaignK L Baker, D T Casey, D S Clark, et al.Physical Review Letters|August 27, 2025
Direct Experimental Proof of the Principal Role of Reduced High-Mode Hydrodynamic Mix in Recent Ignition Success on NIFB Bachmann, L Divol, A Pak, et al.JAMA Network Open|December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast CancerBeverly Kyalwazi, Christina Yau, Michael J Campbell, et al.The Review of Scientific Instruments|January 6, 2025
Ultra-fast single-crystal CVD diamonds in the particle time-of-flight (PTOF) detector for low yield burn-history measurements on the NIF (invited)B L Reichelt, R Kishimori, Y Lawrence, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancerA C Garrido-Castro, S E Kim, T Li, et al.Physical Review Letters|September 19, 2015
Improved Performance of High Areal Density Indirect Drive Implosions at the National Ignition Facility using a Four-Shock Adiabat Shaped DriveD T Casey, J L Milovich, V A Smalyuk, et al.Cancer Cell|June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Christina Yau, Denise M Wolf, et al.Nature Methods|April 12, 2018
A toolbox of immunoprecipitation-grade monoclonal antibodies to human transcription factorsAnand Venkataraman, Kun Yang, Jose Irizarry, et al.Pageof 196